Stock COSMO PHARMACEUTICALS SA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News COSMO Pharmaceuticals SA Swiss Exchange

Equities

LU1202320294

End-of-day quote Swiss Exchange
Other stock markets
- CHF - Intraday chart for COSMO Pharmaceuticals SA
06-18 Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China MT
06-03 Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cosmo's oral diagnostic drug Lumeblue receives approval of New Drug Application in China
AQ
Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China
MT
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
NE
Cosmo Pharmaceuticals N : oral diagnostic drug Lumeblue® receives approval of New Drug Application in China
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Written Proxy
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Proposed Amendments to the Renumeration Policy
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Notification of number of shares as of 6 June 2024
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Explanatory Notes
PU
Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Convening Notice
PU
Cosmo Pharmaceuticals N : Written proxy – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Proposed Amendments to the Remuneration Policy – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Notification of number of shares 6 June 2024 – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Explanatory notes – EGM 5 July 2024
PU
Cosmo Pharmaceuticals N : Convening notice – EGM 5 July 2024
PU
Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down
MT
Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX
NE
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
NE
Cosmo Pharmaceuticals N : reports excellent final Full Year 2023 financial results – Increases operating profit guidance for 2024 – Dividend of € 2.00 per share will be proposed at EGM on 5 July 2024
PU
Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting
NE
Cosmo Pharmaceuticals N : ’ Shareholders approve all Agenda Items at Annual General Meeting
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COPN Stock
  4. Stock
  5. News COSMO Pharmaceuticals SA